Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 20/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.49 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.49 |
| ▸ | AR | P10275 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6770275 | 0.84 | PGR (1.00) | PGRNR3C1NR3C2AR | |
| SCHEMBL6770186 | 0.82 | PGR (1.00) | PGRNR3C1NR3C2AR | |
| SCHEMBL6769679 | 0.81 | PGR (0.98) | PGRNR3C1NR3C2AR | |
| SCHEMBL3873645 | 0.80 | PGR (0.69) | PGRNR3C1NR3C2AR | |
| SCHEMBL3870266 | 0.80 | PGR (0.67) | PGRNR3C1NR3C2AR | |
| SCHEMBL5227050 | 0.74 | PGR (0.76) | PGRNR3C1NR3C2AR | |
| SCHEMBL4101396 | 0.74 | PGR (1.00) | PGRNR3C1NR3C2AR | |
| SCHEMBL5228182 | 0.73 | PGR (0.74) | PGRNR3C1NR3C2AR | |
| SCHEMBL4098486 | 0.72 | PGR (0.73) | PGRNR3C1NR3C2AR | |
| SCHEMBL4098488 | 0.72 | PGR (0.73) | PGRNR3C1NR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094983-A1 | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators | LIGAND PHARMACEUTICALS INCORPORATED | 2002-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094983-A1 | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators | PGR, NR3C1, NR3C2 | PGR 1/4885NR3C1 2/4885NR3C2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.